{"abstract":"This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Antares Pharma Inc., a company having a place of business in Ewing, New Jersey, to practice the inventions embodied in the following patent applications and patents: 1. U.S. Patent Application 11/137,114, filed May 25, 2005, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-US-01]; 2. European Patent 1896025, issued December 28, 2011, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-EP-03]; 3. German Patent 1896025, issued December 28, 2011, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-DE-07]; 4. French Patent 1896025, issued December 28, 2011, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-FR-08]; 5. British Patent 1896025, issued December 28, 2011, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-GB-09]; and 6. Canadian Patent Application 2610025, filed May 18, 2006, titled \"Scopolamine for the Treatment of Depression and Anxiety\" [HHS Ref. No. E-175-2004/0-CA-04. The patent rights in these inventions have been assigned to the Government of the United States of America. The territory of the prospective Exclusive Patent License may be worldwide, and the field of use may be limited to: \"The use of scopolamine for treatment of depression, including major depressive disorder, wherein the route of administration is subcutaneous, intramuscular, or transdermal delivery such as through injection or a patch or topical gel-based product\". This announcement is the second notice to grant an exclusive license to this technology.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/08/27/2013-20880.html","cfr_references":[],"citation":"78 FR 52939","comment_url":null,"comments_close_on":"2013-09-26","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2013 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2013-20880","effective_on":null,"end_page":52939,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/08/27/2013-20880.xml","html_url":"https://www.federalregister.gov/documents/2013/08/27/2013-20880/prospective-grant-of-exclusive-patent-license-use-of-scopolamine-to-treat-depression","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-20880?publication_date=2013-08-27","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-08-27/2013-20880/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":380,"last_updated":"2026-04-04 02:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-08-27/pdf/2013-20880.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-20880.pdf?1377521502","publication_date":"2013-08-27","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/08/27/2013-20880.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2013-09-28T05:01:36Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":52939,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Use of Scopolamine to Treat Depression","toc_doc":"Use of Scopolamine to Treat Depression","toc_subject":"Prospective Grant of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":78}